Please assess the completion status of the following clinical trial:

Trial Title: 20089 TA+Lucentis Combo Intravitreal Injections for Treatment of Neovascular Age-related Macular Degeneration (AMD)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or Female subjects, 55 years of age and older.~2. Diagnosis of active, subfoveal choroidal neovascular membranes (CNVM) due to age related macular degeneration (AMD)~3. Visual acuity from 20/25 to 20/400 in the study eye.~Exclusion Criteria:~1. Subjects who have received corticosteroids via any route in the past 30 days.~2. In the opinion of the investigator, patient is known to be a steroid-responder.~3. Subjects with a history of uncontrolled glaucoma (Primary or Secondary)~4. History of ocular surgery (invasive or non-invasive) in the past 90 days~5. Intravitreal treatment with an anti-VEGF agent e.g. bevacizumab, ranibizumab, or pegaptanib within 30 days of the enrollment (Day 0) examination.~6. Patients requiring systemic steroids (greater than 15 mg daily by mouth) or systemic immunomodulatory agents.~7. Active ocular or periocular infection (i.e., bacterial, viral, parasitic or fungal) in either eye or a history of herpetic ocular infection in either eye.~8. Media opacity in the study eye precluding observation or photography of the fundus.~9. Any other clinically significant medical or psychological condition that, in the opinion of the Investigator, would jeopardize the safety of the patient or affect the validity of the study results.~10. Participation in a clinical trial of an investigational drug or device within 30 days of the screening visit.~11. Known history of allergy to corticosteroids.~12. Pregnant or lactating women

- Gender: ALL
- Minimum Age: 55 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- IBI-20089/Lucentis (Type: EXPERIMENTAL): Alternate treatment of either 6.9 mg IBI-20089/Lucentis or 13.8 mg IBI-20089/Lucentis

Based on this trial design, predict the completion outcome and termination type (if applicable).